Natco Pharma has informed that it enclosed the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The official(s) of the Company will be participating in the investor meetings: 28 to 29 November 2023. The schedule of the above-mentioned meetings is subject to change and the change may occur due to exigencies on the part of Investor/ Company. No Unpublished Price Sensitive Information (UPSI) is intended to be discussed during the interactions.
The above information is a part of company’s filings submitted to BSE.
